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1050-122 Outcomes With Patients of Variable Body Surface Area 
and Long-Term Use of the DeBakey Ventricular Assist 
Device®
Edward Teitel, Marco Turina, Roland Hetzer, George Noon, Hans Scheld, Ettore Vitali, 
Ernst Wolner, MicroMed Technology, Inc., Houston, TX
Background: Ventricular assist devices (VADs) are now accepted treatment for end-
stage heart failure as bridge-to-transplant.Based on the REMATCH trial, the HeartMate®
device has been approved by the FDA for destination therapy. New generation devices
offer the hope for smaller, more reliable support as we move to new indications such as
destination therapy. The miniaturized, continuous flow DeBakey VAD® has been the
most widely used new generation VAD, with over 200 implants worldwide.
Methods: The clinical report forms for completed patients and notes from weekly patient
monitoring conferences for ongoing patients were examined on 157 patients at 6 sites in
Europe.
Results: At pump speeds ranging from 8-11,500rpm (mean 9600 rpm) regardless of
BSA, pump output (mean 4.5 l/min) increased with increasing BSA (slope 1.77)(p <
0.001). Mean arterial pressures and end organ function, as indicated by BUN, creatinine,
and total bilirubin remained in the normal range regardless of BSA. Twenty-five patients
were supported > 6 months and 6 patients were supported > 1 year. Of the 25 who were
supported > 6 months, 16 (64%) went on to transplant, 2 (8%) are still on support, and 7
(28%) died. Five of the patients on support over a year were transplanted and one died.
Forty-three were discharged for a total of 3821 discharge days, or 10.46 patient-years.
(2-342 days). (Some patients were not eligible for discharge because of institutional or
regulatory constraints.) Twenty-five patients had 50 hospital readmissions. These read-
mitted patients spent 2974 days out of the hospital (8.15 patient-years). 70% of those dis-
charged, were either transplanted or remain well on long-term support at home.
Conclusion: The DeBakey VAD adequately supports patients from 1.2-2.3 m2 BSA.
DeBakey VAD patients on long-term support can be successfully managed at home with
excellent outcomes.
1050-123 Neurological Events With a Totally Implantable Left 
Ventricular Assist System: The European LionHeart 
Clinical Utility Baseline Study (CUBS)
John P. Boehmer, Walter E. Pae, Jr., R. Koerfer, A. El-Banayosy, R. Hetzer, M. Vigano, A. 
Pavie, Penn State Milton S. Hershey Medical Center, Hershey, PA, Bad Oeynhausen 
Heart Center, Bad Oeynhausen, Germany
We recorded neurological events in patients with end-stage heart failure not eligible for
transplant undergoing left ventricular assist device (LVAD) placement with the totally
implantable pulsatile LionHeart LVAS as alterntive to medical therapy (AMT).
Twenty-three patients underwent implantation of the LVAS in a non-randomized, observa-
tional study. Neurologic events were pre-specified as a class of adverse events, reported
by sites, and adjudicated independently. The events were further sub-classified as stroke
(CVA), transient ischemic attack (TIA), intracranial bleed (ICB), or other (e.g., brain
abscess), and whether they were either permanent/disabling or transient/reversible.
there were 24 neurologic events in 13 patients (56.5%). Nine patients experienced either
ICB or CVA, five of which also had a TIA. There were a total of 12 TIAs occuring in eight
patients, five of who also had either an ICB or CVA. Three patients were reported to have
an "other" neurologic event. A total of 11 patients had either a CVA or a TIA as a primary
event, producing an event rate of 0.69 events per pateint-year of follow-up. Placed in
terms of functional outcomes, 8 of the LVAD patients had a permanent/disabling neuro-
logical injury and 7 had a transient/reversible episode. Importantly, at least 1/3 of events
(8/24) occuring in four patients were preventable with improved patient selection and
management.
Neurologic events constitute a significant portion of adverse outcomes in this population
of AMT following LVAD placement. TIA is the most common neurologic event, with 12
events occuring in eight patients. The incidence is similar to that of the REMATCH LVAD
group where 52.9% of patients had neurological dysfunction and 21% were reported to
have experienced either an ICB or at least one TIA. Improvements in device design and
patient selection as well as management will be needed to reduce the risk of neurologic
events in patients supported with LVADs as AMT.
1050-124 Left Ventricular Ejecting Force of the Intra-Aortic 
Balloon Pump Assisted and Nonassisted Beats
Ashraf W. Khir, Michael Y. Henein, Derek G. Gibson, John R. Pepper, Royal Brompton 
Hospital, London, United Kingdom, Brunel University, Uxbridge, United Kingdom
Background: The benefits of the Intra Aortic Balloon Pump (IABP) have been widely
demonstrated, but the underlying mechanisms of these benefits are not fully described.
The left ventricle (LV) ejects the stroke volume with a force that is equal to blood mass
multiplied by its acceleration.
Methods: Aortic root, LV early diastolic filling (E-wave) and left anterior descending coro-
nary (LAD) flow velocities were recorded in 20 patients requiring IABP in the intensive
care unit using transesophageal Doppler echocardiography. Recordings were made at
pumping rates 1:2 and 1:3, leaving a minimum of 15 minutes between recordings to allow
for the return to control state. Flow acceleration at the aortic root was calculated as the
slope of the early part of the velocity curve and velocity time integral (VTI) was calculated
to indicate stroke volume. Diastolic VTI of LAD and LV E-wave velocity curves were also
calculated to indicate LAD and LV filling flow.
Results: LAD peak diastolic flow velocity and its VTI increased significantly at IABP 1:2
by (22±2%), (79±15%), and 1:3 by (17±2%), (67±10%) respectively, compared to non
assisted beats. LV E-wave peak velocity and its VTI increased significantly at IABP 1:2 by
(20±5%), (75±6%), and 1:3 by (11±4%), (60±4%) respectively, compared to non assisted
beats. Although a change in flow acceleration at the aortic root was not observed
between the assisted and non assisted beats, peak velocity and VTI increased signifi-
cantly at IABP 1:2 by (25±4%), (35±5%) and 1:3 by (20±3%), (25±4%) respectively, com-
pared to non assisted beats. The increase in LAD diastolic VTI correlated with the
increase in diastolic E-wave VTI (r = 0.82), which correlated with the increase in aortic
root systolic VTI (r=0.87).
Conclusion: The increase in LAD diastolic flow due to balloon inflation results in an
increase in LV filling flow. The increase in LV filling augments the stroke volume ejected
into the aorta, which is in agreement with Starling law. The increase in the stroke volume
despite the unchanged aortic flow acceleration suggests an increase in the LV ejecting
force of the assisted beats, elucidating one of the benefit of IABP.
1050-125 Clinical Application of a Wear-Resistant Axial Flow 
Pump With an Intelligent Control Algorithm as a Left 
Ventricular Cardiac Assist Device
Johannes Mueller, Yu-Guo Weng, Torsten Drews, Dagmar Kemper, Evgeni Potapov, 
Michael Jurmann, Roland Hetzer, Deutsches Herzentrum Berlin, Berlin, Germany
Background: Since the early application of assist devices it has been a goal to have a
totally wear-resistant system. INCOR, an axial flow pump for left heart support, has a vir-
tually unlimited life due to magnetic suspension of the rotating impeller. Patients with
axial flow pumps show a reduced pulsatility of the blood flow. In order to avoid significant
arrhythmia due to sucking in of myocardial tissue INCOR is implemented with an anti-
suction control algorithm.
Methods: Out of 72 patients supported with the device since June 2002, 31 (1f, 30m;
mean age 53, range 36–65 years) with end-stage heart failure received the system in this
institute. Anticoagulation consisted of heparin postoperatively and of Aspirin, clopidogrel,
and Warfarin later on. For dosage adjustment, INR, thrombelastography and platelet
aggregometry were performed. Furthermore, anti-heart-failure medication was adminis-
tered.
Results: Mean follow-up is 127 (range, 12-454) days; 19 patients are still being sup-
ported. Two patients could be weaned because of cardiac improvement after 178 and
206 days. Two were transplanted and eight died due to multi-organ failure after a mean of
49 (range 22 – 126) days. Three patients showed signs of a transitory ischemic attack
and two had cerebral bleeding. Due to the implemented anti-suction algorithm suction did
not occur in any patient. After 2 months, blood chemistry showed normal values for all
organ functions, in particular no hemolysis (LDH, LDH1 normal) and no deviation of any
blood cell count. None of the patients showed signs of infection (CRP normal). Auto-anti-
bodies against cardiac structures like the beta-1-adrenoceptor disappeared within six
weeks after the implantation.
Conclusions: Application of up-to-date technology in the design of axial flow pumps sig-
nificantly improves the clinical outcome. Especially the problems resulting from chronic
systemic infection and elevated inflammatory status, known as a major problem of car-
diac assist device therapy, seem to be solved. The disappearance of the antibodies after
only six weeks is a sign of a fast immunological recovery. No side effects due to reduced
pulsatility of the blood could be observed.
1050-126 Left Ventricular Assist Device Implantation in Patients 
With Viral Myocarditis-Induced Heart Failure
Nicholas C. Dang, Ranjit John, Jeffrey A. Morgan, Brian J. Lee, Mehmet C. Oz, Yoshifumi 
Naka, Columbia-Presbyterian Medical Center, New York, NY
Background: Viral myocarditis (VM) is a disease entity that exhibits a broad range of
clinical pathways to the onset of cardiac symptoms, but the progression to severe con-
gestive heart failure, both chronic and acute, carries significant morbidity and mortality.
Left ventricular assist device (LVAD) implantation has gained acceptance as a modality
Implantation 30 days 
Post-
Implantation
60 days 
Post-
Implantation
90 days 
Post-
Implantation
Explantation
 Echocardiographic 
Analysis:
LVEF (%) 19.3±6.62 43.5±8.51*** 40.7±10.9*** 36.0±12.7*** -
LVEDD (mmHg) 6.94±1.40 3.31±0.97*** 4.42±1.00*** 4.90±1.40** -
LV mass (gm) - 193±102 192±90.1 220±90.1 -
 Tissue Analysis:
Myocyte Area (µm2) 562±122 - - - 290±63.3***
Myocyte Diameter (µm) 16.9±2.49 - - - 13.0±1.87***
% Collagen Deposition 35.7±7.14 - - - 27.1±4.27***
 Serological 
Analysis:
BNP levels (pg/mL) 225±148 63.8±42.7* - - 16.3±7.71**
 Electrophysiologic 
Analysis:
QTc (msec) 472±56.0 448±48.1 434±34.5* - 461±70.0
QRS (msec) 121±30.4 104±20.3** 104±17.4** - 114±45.4
Notes: Values are the 
means ± SD of the 
listed parameters.
All p-values are 
for t-tests vs 
values at 
implantation.
* p-value < 
0.05.
**p-value < 
0.01.
***p-value < 
0.001.
